Αρχική World News Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised... World News Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC Από Ogkologos - 19 Μαΐου, 2026 341 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PLANeT study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... 8 Οκτωβρίου, 2025 EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... 17 Νοεμβρίου, 2023 EMA Recommends Extension of Indications for Cemiplimab 27 Μαΐου, 2021 New on NCI’s Websites for December 2023 28 Δεκεμβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Finding New Uses for Targeted Therapies for Cancer: Updates from the... Taking pride in all of our researchers ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology... Hundreds Of Thousands Of Peruvian Women Were Forcibly Sterilized, And Now...